Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508725 · ClinicalTrials.gov registry record · NA
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
A NA study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04508725: Completed NA study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Stanford University.
NCT04508725 is a NA study of Renal Cell Carcinoma and Kidney Cancer that has completed, run by Stanford University. The registered enrollment target is 22 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04508725, a NA study of Renal Cell Carcinoma and Kidney Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Primary Outcome
Initial objective response was defined as having either Complete Response (CR) or Partial Response (PR) per RECIST v1.1 at first on-treatment response evaluation 8-16 weeks after initiating treatment.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Doppler Ultrasound
- DEVICE SIEMENS S3000 and Verasonics Vantage 256
- DRUG Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- DRUG Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-12-05 |
| Est. Completion | 2023-11-30 |
| Phase | NA |
What the finished NCT04508725 record still lists
NCT04508725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Doppler Ultrasound is the first listed.
NCT04508725 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04508725 about?
NCT04508725 is a clinical study titled "Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)". To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
What is the current status of trial NCT04508725?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2020-12-05. Estimated completion is 2023-11-30.
What conditions does trial NCT04508725 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer, Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT04508725?
The interventions under investigation include: Doppler Ultrasound (DIAGNOSTIC_TEST), SIEMENS S3000 and Verasonics Vantage 256 (DEVICE), Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) (DRUG), Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI (DRUG).
Who is sponsoring clinical trial NCT04508725?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04508725 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04508725's enrollment target sits among peer trials
22 105th of 121 higher than 15 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
RECRUITING · NA
-
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
RECRUITING · NA
-
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI